$XBI $89.62 | -2.34%
Covid Updates
$VIR US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
$NVAX Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine
$ICVX Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
Pipeline Updates
$BPMC Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis
$INMB INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
$EXEL Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
$INCY Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
$LEGN CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
$MORF MORPHIC THERAPEUTIC ANNOUNCES INITIATION OF EMERALD-1 PHASE 2A CLINICAL TRIAL OF MORF-057 IN PATIENTS WITH ULCERATIVE COLITIS
$ARQT Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
$ARQT Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
$TLSA Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
$ADMA ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months
Business Updates
$SLGL Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
$SRNE Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage
$HRTX Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care
$HTBX Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
$JAZZ Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing
Posted by DV
Comentários